Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria supplement shows promise for weight management

NCT ID NCT06653101

Disease control Sponsor: Wecare Probiotics Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a probiotic called Akkermansia muciniphila Akk11 can help overweight or obese adults improve their metabolism and gut health. 110 participants took either the probiotic or a placebo daily. Researchers measured changes in appetite-related hormones and other health markers to see if the supplement made a difference.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

110 people

The number who actually took part.

Started

Oct 2024

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18-45 years old; 2. BMI ≥ 24 kg/m2 or men with a body fat percentage of ≥ 25% and women with a body fat percentage of ≥ 30%； 3. Normal liver function indexes; 4. Willing to complete study-related questionnaires and diaries and complete all clinical visits. Exclusion Criteria: 1. Those who have been diagnosed with high uric acid or gout are not recommended to participate in the test; 2. Psychiatric or neurological diseases, celiac disease, lactose intolerance, allergies; 3. Have the following diseases: irritable bowel syndrome, ulcerative colitis, fatty liver, liver cirrhosis, etc.; 4. Recently treated with antibiotics (i.e., \< 3 months prior to the start of the study); 5. Participants who smoked more than 10 cigarettes per day were excluded; 6. It is not recommended to participate in other special circumstances, such as those who are allergic to probiotic products; 7. Pregnant and lactating women are not suitable for experiments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight or obesity

Contacts and locations

Locations

  • Fei Xu

    Zhengzhou, None Selected, 210095, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.